AstraZeneca closes in on site for new home in Cambridge
By Ben Hirschler and Tom Bill LONDON (Reuters) - AstraZeneca is closing in on a site for its new $500 million home in Cambridge, wit...
Read More »By Ben Hirschler and Tom Bill LONDON (Reuters) - AstraZeneca is closing in on a site for its new $500 million home in Cambridge, wit...
Read More »By Lawrence Hurley WASHINGTON (Reuters) - The U.S. Supreme Court on Monday agreed to hear a patent dispute concerning Medtronic Inc ...
Read More »(Reuters) - Peregrine Pharmaceuticals said it reached an agreement with the U.S. Food and Drug Administration on the design of a lat...
Read More »By Toni Clarke WASHINGTON (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to r...
Read More »By Vrinda Manocha (Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned...
Read More »By Caroline Humer and Ransdell Pierson (Reuters) - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it...
Read More »
By Padraic Halpin and Jessica Toonkel DUBLIN/NEW YORK (Reuters) - Royalty Pharma raised its hostile bid for Elan to $12.50 per share...
Read More »
By Dorene Internicola NEW YORK (Reuters) - Fitness experts are shining a new light on group classes from Zumba to yoga because they ...
Read More »By Genevra Pittman NEW YORK (Reuters Health) - Boys who are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in elemen...
Read More »By Genevra Pittman NEW YORK (Reuters Health) - A newer version of the whooping cough vaccine doesn't protect kids as well as the ori...
Read More »